Allogeneic Transplantation Using Venetoclax, Timed Sequential Busulfan,Cladribine, and Fludarabine Conditioning in Patients With AML and MDS
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2019
Price : $35 *
At a glance
- Drugs Busulfan (Primary) ; Cladribine (Primary) ; Fludarabine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 14 Feb 2018 Planned End Date changed from 1 Oct 2019 to 1 Oct 2020.
- 27 Oct 2014 Planned primary completion date changed from 1 Dec 2019 to 1 Oct 2019, as per ClinicalTrials.gov record.
- 27 Oct 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.